Orexo and Sobi agree to advance feasibility study with AmorphOX
UPPSALA, Sweden, Feb. 12, 2024 /PRNewswire/ — Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces the company agreed with Swedish Orphan Biovitrum AB (publ.) (Sobi) to advance the successful exploratory feasibility study initiated last year. The feasibility study primarily assessed whether the biomolecule could be formulated in AmorphOX with retained activity. The continued collaboration will evaluate if the AmorphOX technology could add unique properties to one of Sobi’s biomolecules.
Related news for (ORXOY)
- Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose
- Orexo AB´s sustainability work ranked among top 5% by EcoVadis
- Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm
- Orexo announces that the condition for early redemption of its existing bonds has been fulfilled
- Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds